BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ramos H, Linares P, Badia E, Martín I, Gómez J, Almohalla C, Jorquera F, Calvo S, García I, Conde P, Álvarez B, Karpman G, Lorenzo S, Gozalo V, Vásquez M, Joao D, de Benito M, Ruiz L, Jiménez F, Sáez-Royuela F, Asociación Castellano y Leonesa de Hepatología (ACyLHE). Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting. World J Gastrointest Pharmacol Ther 2017; 8(2): 137-146 [PMID: 28533924 DOI: 10.4292/wjgpt.v8.i2.137]
URL: https://www.wjgnet.com/2150-5349/full/v8/i2/137.htm
Number Citing Articles
1
Kellie Young, Benny Liu, Taft Bhuket, Robert G. Gish, Robert J. Wong. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct‐acting antiviral therapies in the United StatesJournal of Viral Hepatitis 2019; 26(3): 350 doi: 10.1111/jvh.13039
2
Jose Luis Calleja, Jaime Espin, Ankita Kaushik, Manuel Hernandez-Guerra, Rob Blissett, Alon Yehoshua, Adam Igloi-Nagy. The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination GoalsPharmacoEconomics - Open 2024; 8(2): 221 doi: 10.1007/s41669-023-00458-3
3
Rion Masaoka, Yoshinori Gyotoku, Ryosaku Shirahashi, Toshikuni Suda, Masaya Tamano. Combining the age-male-albumin-bilirubin-platelets score and shear wave elastography stratifies carcinogenic risk in hepatitis C patients after viral clearanceWorld Journal of Clinical Cases 2023; 11(22): 5198 doi: 10.12998/wjcc.v11.i22.5198
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
4
Maia Butsashvili, Lia Gvinjilia, George Kamkamidze, David Metreveli, Shorena Dvali, Tamar Rukhadze, Amiran Gamkrelidze, Muazzam Nasrullah, Shaun Shadaker, Juliette Morgan, Francisco Averhoff. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in GeorgiaBMC Research Notes 2020; 13(1) doi: 10.1186/s13104-020-05173-4
5
Hugo Perazzo, Marcelino Jose Jorge, Julio Castro Silva, Alexandre Monken Avellar, Patrícia Santos Silva, Carmen Romero, Valdilea Gonçalves Veloso, Ruben Mujica-Mota, Rob Anderson, Chris Hyde, Rodolfo Castro. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in BrazilBMC Gastroenterology 2017; 17(1) doi: 10.1186/s12876-017-0676-8
6
Romeo-Gabriel Mihăilă. Liver stiffness in chronic hepatitis C virus infectionRomanian Journal of Internal Medicine 2019; 57(2): 85 doi: 10.2478/rjim-2018-0034
7
Reza Taherkhani, Fatemeh Farshadpour. Global elimination of hepatitis C virus infection: Progresses and the remaining challengesWorld Journal of Hepatology 2017; 9(33): 1239-1252 doi: 10.4254/wjh.v9.i33.1239
8
Rafael Esteban, Raquel Domínguez-Hernández, Victoria Martín-Escudero, Miguel Ángel Casado, Matteo Ruggeri. Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in SpainPLOS ONE 2022; 17(12): e0278544 doi: 10.1371/journal.pone.0278544
9
Rion Masaoka, Yoshinori Gyotoku, Ryosaku Shirahashi, Toshikuni Suda, Masaya Tamano. Combining the age-male-albumin-bilirubin-platelets score and shear wave elastography stratifies carcinogenic risk in hepatitis C patients after viral clearanceWorld Journal of Clinical Cases 2023; 11(22): 5204-5214 doi: 10.12998/wjcc.v11.i22.5204
10
Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in SpainGastroenterología y Hepatología (English Edition) 2017; 40(7): 433 doi: 10.1016/j.gastre.2017.07.008
11
Ulrich Spengler. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infectionPharmacology & Therapeutics 2018; 183: 118 doi: 10.1016/j.pharmthera.2017.10.009
12
Yoshinori Gyotoku, Ryosaku Shirahashi, Toshikuni Suda, Masaya Tamano. Role of liver stiffness measurements in patients who develop hepatocellular carcinoma after clearance of the hepatitis C virusJournal of Medical Ultrasonics 2022; 49(2): 253 doi: 10.1007/s10396-021-01188-x
13
Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado. Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en EspañaGastroenterología y Hepatología 2017; 40(7): 433 doi: 10.1016/j.gastrohep.2017.05.004
14
Bryan Tolentino, Ritu R Singh, Suresh Misra, Douglas T Dieterich, Dost Sarpel. An Update On the Management of Hepatitis C Virus and Human Immunodeficiency Virus co-infectionFuture Virology 2019; 14(3): 185 doi: 10.2217/fvl-2018-0116
15
I. A. Narkevich, E. A. Tsitlionok. Development of approaches to the evaluation of pharmacotherapy effectiveness for chronic hepatitis CFARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 2023; 16(4): 607 doi: 10.17749/2070-4909/farmakoekonomika.2023.193
16
Kellie Young, Benny Liu, Taft Bhuket, Robert J. Wong. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting AntiviralsJournal of Clinical and Experimental Hepatology 2020; 10(6): 581 doi: 10.1016/j.jceh.2020.02.003